Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
:PHGE
PHGE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.48 - $4.99
Previous CloseN/A
Volume30.96K
Average Volume (3M)163.51K
Market Cap
$13.22M
Enterprise Value$23.69M
Total Cash (Recent Filing)$896.73K
Total Debt (Recent Filing)$500.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 14, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.96
Shares Outstanding24,996,054
10 Day Avg. Volume334,754
30 Day Avg. Volume163,511
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.29
Enterprise Value/Ebitda-5.33
Forecast
1Y Price Target
$21.00Price Target Upside3788.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
BiomX News
PremiumCompany Announcements
BiomX Announces Positive Phase 2 Trial Results
PremiumPre-Earnings
Is PHGE a Buy, Before Earnings?
PremiumCompany Announcements
BiomX Announces $12M Funding for BX004 Study
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBiomX announced 3Q24 financial results, posting EPS of $0.31 compared with an estimate of ($0.06).
Phase 2 DataBiomX announced positive results from its Phase 2 trial of BX211 for diabetic foot osteomyelitis (DFO) associated with S. aureus.
Bears Say
Investor SentimentInvestor sentiment was negative, which is likely due to the p-values for the key endpoints.
Manufacturing DelaysDue to manufacturing delays, the topline data from the BX004 study are now expected by 1H26.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PHGE FAQ
What was BiomX’s price range in the past 12 months?
BiomX lowest stock price was $0.48 and its highest was $4.99 in the past 12 months.
What is BiomX’s market cap?
BiomX’s market cap is $13.22M.
When is BiomX’s upcoming earnings report date?
BiomX’s upcoming earnings report date is May 14, 2025 which is in 31 days.
How were BiomX’s earnings last quarter?
BiomX released its earnings results on Mar 25, 2025. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of -$1.095 by $1.545.
Is BiomX overvalued?
According to Wall Street analysts BiomX’s price is currently Undervalued.
Does BiomX pay dividends?
BiomX does not currently pay dividends.
What is BiomX’s EPS estimate?
BiomX’s EPS estimate is -0.36.
How many shares outstanding does BiomX have?
BiomX has 24,996,054 shares outstanding.
What happened to BiomX’s price movement after its last earnings report?
BiomX reported an EPS of $0.45 in its last earnings report, beating expectations of -$1.095. Following the earnings report the stock price went down -7.937%.
Which hedge fund is a major shareholder of BiomX?
Currently, no hedge funds are holding shares in PHGE
---
Company Description
BiomX
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
---
PHGE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of positive developments and challenges. Key achievements include completing patient enrollment for a crucial trial and securing additional funding, along with a net income turnaround. However, manufacturing delays and increased expenses pose challenges. Despite these issues, the company's positive clinical results and financial runway provide a strong outlook.Read More>---
PHGE Stock 12 Month Forecast
Average Price Target
$21.00
▲(3788.89% Upside)
Technical Analysis
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Foghorn Therapeutics
―
Best Analysts Covering PHGE
1 Year
1 Year Success Rate
3/20 ratings generated profit
1 Year Average Return
-54.17%
reiterated a buy rating 8 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -54.17% per trade.
---